Summit shareholders double authorized shares to 2 billion

Shareholders of Summit Therapeutics (NASDAQ:SMMT) approved doubling authorized common shares to 2 billion from 1 billion at its 2026 special meeting, according to preliminary voting results. The amendment to its restated certificate of incorporation was the only business item, Chairman and Co-CEO Bob Duggan said: “It was the only item of business put to a vote at the meeting.”

What does the vote change for shareholders?

The vote expands the legal ceiling on common stock, a distinction comparable to an expanded credit line rather than a drawn loan. It creates room for future equity issuance, but the result itself does not raise cash.

Summit disclosed no issue size, price or timetable. If Summit later issues shares from the added capacity, existing holders could face dilution.

What did the preliminary result establish?

Chief Business and Strategy Officer Dave Gancarz said the inspector of election’s preliminary report “determined that the amendment had been approved.” The company did not provide a vote count during the meeting, leaving final totals for the planned follow-up disclosure.

Summit intends to disclose final results in a Form 8-K (the Securities and Exchange Commission filing used for material corporate events) within four business days of the meeting. After filing, the company will place a link under Investor Information, Reports and Filings on its website.

How did the special meeting proceed?

Summit mailed the meeting notice and proxy statement on or about October 19, 2026, to shareholders of record at the close of business on October 1, 2026. Adam Finerman, an attorney with outside counsel BakerHostetler, served as inspector of election.

Finerman reported that proxies representing a majority of the total votes entitled to be cast had been received, establishing a quorum (the minimum voting participation required to conduct the meeting). The proxy presentation established the voting threshold for the meeting.

Duggan said shareholders present could vote, as could shareholders represented by proxy. After voting closed and the preliminary result came in, Duggan accepted the inspector’s report and asked that it be recorded in the meeting minutes.

Co-CEO and President Dr. Maky Zanganeh and Chief Operating Officer and Chief Financial Officer Manmeet Soni attended the meeting. Both also serve on Summit’s board.

Gancarz served as secretary. After formal business concluded, Duggan allowed time for shareholder questions. Gancarz said there were none, and Duggan said he had received none.

Where does ivonescimab stand?

Summit Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative medicines for cancer. Its primary focus is oncology (cancer treatment), with an emphasis on therapies designed to improve outcomes for patients with serious diseases.

Ivonescimab is Summit’s lead product candidate and a bispecific antibody (a molecule designed to engage two biological targets). It is designed to combine immune checkpoint inhibition against PD-1 (an inhibitory immune checkpoint) with anti-angiogenic activity targeting VEGF (a signal involved in blood-vessel growth).

Summit is advancing ivonescimab in clinical studies for non-small cell lung cancer (NSCLC) and evaluating the therapy in combination with other cancer treatments. The company is also assessing additional treatment settings.

Which rights does Summit hold outside China?

Summit holds exclusive rights to develop and commercialize ivonescimab in markets outside China through a licensing and collaboration agreement with Akeso, a China-based biopharmaceutical company. The arrangement places control of development and commercialization outside China with Summit. Summit disclosed no milestone, royalty or other financial terms.

What should finance teams watch?

The immediate checkpoint is the final vote count, expected in a Form 8-K within four business days. Beyond that disclosure, any capital-raising announcement would need to identify the size and use of the expanded authorization; this vote establishes legal capacity rather than a completed issuance.